Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has agreed to pay Quell Therapeutics up to $2.1 billion to develop engineered regulatory T cell therapies for type 1 diabetes and inflammatory…
AstraZeneca said on Friday it had signed a deal worth up to $2.1 billion with Britain's Quell Therapeutics to develop engineered regulatory T-cell therapies…
AstraZeneca selected a lead IBD Treg cell-therapy candidate and exercised its exclusive option to license it for further development and commercialization,…
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca entered an exclusive option and license agreement with Quell to develop engineered Treg cell therapies for autoimmune diseases (T1D and IBD). Quell received $85M upfront (cash + equity) and is eligible for over $2B in development/commercial milestones plus tiered royalties. Since signing, the alliance has advanced on both programs: in November 2024 AstraZeneca selected a lead Type 1 diabetes CAR-Treg candidate to progress, triggering a $10M milestone to Quell; in June 2025 AstraZeneca selected a lead IBD candidate and exercised its exclusive option to license it for further development and commercialization, triggering a second $10M payment. AstraZeneca leads CTA/IND-enabling studies and clinical development while Quell provides CMC support and GMP drug-product supply for first-in-human trials. The collaboration remains active as of mid-2025; no termination has been disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Quell Therapeutics Limited (this deal) | 2023 | $2.1B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Immunology deals